-
Featured
Is Accelerated Infliximab Induction Beneficial for Severe Ulcerative Colitis?
While short-interval administration of infliximab was equally efficacious as standard administration for severe ulcerative colitis, a multicenter retrospective study has shown that a higher dose upon initiation reduced the risk of colectomy.
-
Featured
Discovering the Role of C1orf106 in Patients with IBD
C1orf106 is a known susceptibility gene for inflammatory bowel disease, and now Massachusetts General researchers have identified its role: it "fine tunes" the integrity of the intestinal epithelial barrier.
-
Featured
Obesity Tied to Risk of Diverticulosis
By analyzing a cohort of adults who underwent colonoscopy, gastroenterologists at Massachusetts General Hospital have determined that overweight and obesity substantially increase the risk of diverticulosis.
-
Digital App-based Cognitive Behavioral Therapy Significantly Improves IBS Symptoms
At the American College of Gastroenterology 2023 Scientific Meeting, Mythili Pathipati, MD, presented findings from a real-world study where app-delivered cognitive behavioral therapy resulted in a significant reduction in symptom severity and perceived stress for patients with irritable bowel syndrome.
-
Concurrent Immunosuppressive Therapy With Restart of Checkpoint Inhibitor Reduces Risk of Recurrent Immune-related Enterocolitis
A retrospective study at Massachusetts General Hospital and two other centers found cancer patients who had an immune checkpoint inhibitor restarted after an episode of immune-related enterocolitis had significantly less risk of severe recurrent enterocolitis if they concurrently received infliximab or vedolizumab.
-
Fibrosis Directly Affects Disease Progression in IBD
Researchers at Massachusetts General Hospital determined intestinal stiffening is a critical component of the pathogenesis of inflammatory bowel disease and found evidence that targeting mechanosensing pathways may be an attractive therapeutic strategy.
Bowel Disease Contributors
-
Andrew T. Chan, MD, MPH
Daniel K. Podolsky Professor of Medicine, Harvard Medical School, Director for Cancer Epidemiology, Mass General Cancer Center, Chief, Clinical and Translational Epidemiology Unit, Department of Medicine
Recent Article
PPI, H2RA Use by Older Adults Not Associated With Dementia or Cognitive Impairment
-
Ashwin N. Ananthakrishnan, MBBS, MPH
Director of the Crohn's and Colitis Center, Division of Gastroenterology, Mass General, Associate Professor of Medicine, Harvard Medical School
Recent Article
Role of Biomarkers in Ulcerative Colitis Management
-
Hamed Khalili, MD, MPH
Gastroenterologist, Clinical and Translational Epidemiology Unit, Director of Clinical Research in Inflammatory Bowel Disease in the Division of Gastroenterology, Associate Professor of Medicine, Harvard Medical School
Recent Article
Initiating Oral Contraception Does Not Change Gut Microbiome in Healthy Women
-
Wenjie Ma, MBBS, ScD
Instructor and Investigator in the Clinical and Translational Epidemiology Unit, Assistant in Epidemiology in the Division of Gastroenterology, Instructor in Medicine, Harvard Medical School
Recent Article
Initiating Screening Before Age 50 Reduces Risk of Colorectal Cancer
Digestive Healthcare at Mass General
The Massachusetts General Hospital Digestive Healthcare Center is a collaborative practice of gastroenterologists, endoscopists, surgeons, radiologists, pathologists, hepatologists, oncologists and radiation oncologists dedicated to the prevention, diagnosis, treatment and management of digestive diseases.